A First for Indonesia: Nusraya Fertility Center adopts EMBRYOAID embryo grading AI
Nusraya Fertility Center, one of Indonesia’s leading fertility and IVF clinics, today announced a
major step forward in reproductive medicine with the integration of Artificial Intelligence (AI) into
its IVF program. Through a strategic collaboration with EMBRYOAID, an AI-powered embryo
assessment solution developed by MIM Fertility, Nusraya becomes the first IVF clinic in
Indonesia to adopt this advanced technology.
Find out more about Nusraya Fertility Center
With a strong focus on improving IVF outcomes, transparency, and clinical consistency, Nusraya Fertility Center is positioning itself at the forefront of AI-enabled fertility care in the country.
The integration of EMBRYOAID marks an important milestone in bringing globally recognized
innovation to Indonesian patients.
AI-Powered Embryo grading, to Support Clinical Decision-Making
At the core of this technological advancement is EMBRYOAID, an AI-based embryo grading
platform trained on large datasets of embryo images. The system provides objective,
data-driven insights to support embryologists and physicians during embryo evaluation, one of
the most critical steps in IVF treatment.
Advancing Comprehensive and Responsible Fertility Care
The adoption of AI technology reflects Nusraya Fertility Center’s commitment to offering
comprehensive, evidence-based fertility services aligned with international standards and the
newest technological advancements. By combining experienced specialists, advanced
laboratory infrastructure, and AI-driven support tools, the clinic aims to continuously elevate the
quality of care for patients across Indonesia.
Commenting on the collaboration, Otto John T.B. Hasugian, Vice President and Director of Nusraya Fertility Center, said:
“This collaboration represents our commitment to bringing the most advanced and responsible fertility technologies to Indonesia. By integrating EMBRYOAID into our clinical workflow, we are
strengthening our ability to deliver a more transparent and patient-centered IVF care.”
Ula Sankowska, CEO of MIM Fertility, commented:
“We would like to thank Nusraya Fertility Center for their trust and partnership. Seeing MIM Fertility’s EMBRYOAID implemented for the first time in Indonesia is a powerful milestone. This achievement reflects commitment to innovation and patient care, and we are incredibly proud to support a team that is setting new standards for reproductive medicine in the region.”
See currect medical research for EMBRYOAID
For media and PR inquiries, please contact Paulina Kwasniak.
